Rheumatology, Vol 38, 39-46, Copyright © 1999 by British Society for Rheumatology
L Liaropoulos
In Greece a 15-day treatment of rheumatic disease with diclofenac costs 56%
more than treatment with nimesulide. This is due to the lower incidence of
gastrointestinal adverse events with nimesulide, and the absence of serious
gastrointestinal complications leading to hospitalization, which more than
offset the higher acquisition cost of nimesulide. The average saving by
using nimesulide instead of diclofenac is about US$21 per patient for a
15-day treatment period.
ORIGINAL PAPERS
Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece
Centre for Health Services Management and Evaluation, University of Athens, Faculty of Nursing, Greece.
![]()
CiteULike
Connotea
Del.icio.us What's this?